EMA Application withdrawn: Pioglitazone ratiopharm (pioglitazone) — Ratiopharm GmbH

View source ↗

Summary

The EMA withdrawal indicates the pioglitazone application by Ratiopharm GmbH for Type 2 diabetes has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• PIOGLITAZONE (Pioglitazone)

Snippet

Status: Application withdrawn. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Ratiopharm GmbH. Decision date: 22/07/2011